1. Associations of DMT therapies with COVID-19 severity in multiple sclerosis
- Author
-
Simpson-Yap, S, De Brouwer, E, Kalincik, T, Rijke, N, Hillert, J, Walton, C, Edan, G, Spelman, T, Geyes, L, Parciak, T, Gautrais, C, Lazovski, N, Pirmani, A, Ardeshirdavani, A, Forsberg, L, Glaser, A, McBurney, R, Schmidt, H, Bergmann, A, Braune, S, Stahmann, A, Middleton, R, Salter, A, Fox, R, van der Walt, A, Butzkueven, H, Rojas, J, van der Mei, I, Nag, N, Ivanov, R, do Olival, GS, Dias, AE, Magyari, M, Brum, DG, Mendes, MF, Alonso, R, Nicholas, R, Bauer, J, Chertcoff, A, Zabalza, A, Arrambide, G, Fidao, A, Comi, G, Peeters, L, Simpson-Yap, S, De Brouwer, E, Kalincik, T, Rijke, N, Hillert, J, Walton, C, Edan, G, Spelman, T, Geyes, L, Parciak, T, Gautrais, C, Lazovski, N, Pirmani, A, Ardeshirdavani, A, Forsberg, L, Glaser, A, McBurney, R, Schmidt, H, Bergmann, A, Braune, S, Stahmann, A, Middleton, R, Salter, A, Fox, R, van der Walt, A, Butzkueven, H, Rojas, J, van der Mei, I, Nag, N, Ivanov, R, do Olival, GS, Dias, AE, Magyari, M, Brum, DG, Mendes, MF, Alonso, R, Nicholas, R, Bauer, J, Chertcoff, A, Zabalza, A, Arrambide, G, Fidao, A, Comi, G, and Peeters, L
- Abstract
Background People with multiple sclerosis (MS) are a vulnerable group for severe COVID-19, particularly those taking immunosuppressive disease-modifying therapies (DMTs). We examined the characteristics of COVID-19 severity in an international sample of people with MS. Methods Data from 12 data-sources in 28 countries were aggregated (sources could include patients from 1-12 countries). Demographic (age, sex), clinical (MS phenotype, disability), and DMT (untreated, alemtuzumab, cladribine, dimethyl-fumarate, glatiramer-acetate, interferon, natalizumab, ocrelizumab, rituximab, siponimod, other) covariates were queried, alongside COVID-19 hospitalisation, admission to ICU, requiring artificial ventilation, and death. Characteristics of outcomes were assessed in patients with suspected/confirmed COVID-19 using multilevel mixed-effects logistic regression, adjusted for age, sex, MS phenotype, and EDSS. Results 657 (28.1%) with suspected and 1,683 (61.9%) with confirmed COVID-19 were analysed. Among suspected+confirmed/confirmed-only COVID-19, 20.9%/26.9% were hospitalised, 5.4%/7.2% were admitted to ICU, 4.1%/5.4% required artificial ventilation, and 3.2%/3.9% died. Older age, progressive MS-phenotype, and higher disability were associated with worse COVID-19 outcomes. Compared to dimethyl-fumarate, ocrelizumab and rituximab were associated with hospitalisation (aOR=1.56,95%CI=1.01-2.41; aOR=2.43,95%CI=1.48-4.02) and ICU admission (aOR=2.30,95%CI=0.98-5.39; aOR=3.93,95%CI=1.56-9.89), though only rituximab was associated with higher risk of artificial ventilation (aOR=4.00,95%CI=1.54-10.39). Importantly, associations persisted on restriction to confirmed COVID-19 cases. No associations were observed between DMTs and death. Conclusions Despite the cross-sectional design of this study, the internal and external consistency of these results with prior studies suggests their use may be a risk factor for more severe COVID-19. Key messages Anti-CD20 DMTs may be assoc
- Published
- 2021